| Literature DB >> 26613635 |
Rodrigo Mendoza-Sanchez1, David Cotnoir-White2, Justyna Kulpa2, Isabel Jutras2, Joshua Pottel1, Nicolas Moitessier1, Sylvie Mader3, James L Gleason4.
Abstract
The combination of antiestrogens and histone deacetylase inhibitors (HDACi) has been found to be antiproliferative in breast cancer models. We designed and synthesized hybrid structures which combined structural features of the pure antiestrogen ICI-164,384 and HDACi's SAHA and entinostat in a single bifunctional molecule. The hybrids retained antiestrogenic and HDACi activity and, in the case of benzamide hybrids, were selective for Class I HDAC3 over Class II HDAC6. The hybrids possessed low micromolar to high nanomolar activity against both ER+ MCF-7 and ER- MDA-MB-231 breast cancer cell models.Entities:
Keywords: Antiestrogens; Breast cancer; Estrogen receptor; HDACi
Mesh:
Substances:
Year: 2015 PMID: 26613635 DOI: 10.1016/j.bmc.2015.11.005
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641